Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effective dose of remimazolam plus esketamine for pediatric endotracheal intubation without muscle relaxants
ChiCTR2200063847Phase 4Not yet recruiting
- Sponsor
- The Affiliated Shunde Hospital of Jinan University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam and esketamine (2 arms), sponsored by The Affiliated Shunde Hospital of Jinan University. Primary endpoint: Intubation response. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
remimazolamesketamine
Beyond the preview
Go deeper on ChiCTR2200063847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063847.